4SC gives update on resminostat

4SC AG has been taking scientific advice from regulators about the design of a prospective Phase 3 study of its HDAC inhibitor for liver cancer, resminostat. Pending the conclusion of a partnership, a study could start in the 2013 first half, according to management.

Location